

# Jane L Liesveld

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4017355/publications.pdf>

Version: 2024-02-01

143  
papers

4,848  
citations

136950

32  
h-index

106344

65  
g-index

148  
all docs

148  
docs citations

148  
times ranked

7460  
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. <i>Blood</i> , 2005, 106, 1867-1874.	1.4	427
2	Long-Lived Plasma Cells Are Contained within the CD19 <sup>hi</sup> CD38 <sup>hi</sup> CD138 <sup>+</sup> Subset in Human Bone Marrow. <i>Immunity</i> , 2015, 43, 132-145.	14.3	415
3	Rapid Mobilization of CD34 <sup>+</sup> Cells Following Administration of the CXCR4 Antagonist AMD3100 to Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 1095-1102.	1.6	406
4	An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. <i>Blood</i> , 2007, 110, 4427-4435.	1.4	357
5	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) [J] ETQq1 1 0.784314 rgBT /Over to methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). <i>Lancet Haematology</i> , 2019, 6, e132-e143.	4.6	200
6	Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. <i>Blood</i> , 2016, 128, 1671-1678.	1.4	179
7	Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells. <i>Journal of Biological Chemistry</i> , 2013, 288, 33542-33558.	3.4	163
8	Analysis of Factors That Correlate With Mucositis in Recipients of Autologous and Allogeneic Stem-Cell Transplants. <i>Journal of Clinical Oncology</i> , 1999, 17, 2446-2446.	1.6	149
9	Stem cell homing: From physiology to therapeutics. <i>Stem Cells</i> , 2020, 38, 1241-1253.	3.2	116
10	Expression of Interleukin-7 Receptor by Lineage-Negative Human Bone Marrow Progenitors With Enhanced Lymphoid Proliferative Potential and B-Lineage Differentiation Capacity. <i>Blood</i> , 1997, 89, 929-940.	1.4	86
11	Evolution to plasmablastic lymphoma evades CD19 <sup>hi</sup> -directed chimeric antigen receptor T cells. <i>British Journal of Haematology</i> , 2015, 171, 205-209.	2.5	83
12	Genetic engineering of platelets to neutralize circulating tumor cells. <i>Journal of Controlled Release</i> , 2016, 228, 38-47.	9.9	75
13	Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 535-555.	2.4	75
14	The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680.	5.2	71
15	Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. <i>Leukemia Research</i> , 2007, 31, 1553-1563.	0.8	68
16	Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973.	5.2	63
17	Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871.	1.6	61
18	Bone marrow mesenchymal stromal cells from acute myelogenous leukemia patients demonstrate adipogenic differentiation propensity with implications for leukemia cell support. <i>Leukemia</i> , 2020, 34, 391-403.	7.2	61

#	ARTICLE	IF	CITATIONS
19	Integrins and Adhesive Receptors in Normal and Leukemic CD34+ Progenitor Cells: Potential Regulatory Checkpoints for Cellular Traffic. <i>Leukemia and Lymphoma</i> , 1994, 14, 19-28.	1.3	59
20	Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis. <i>Stem Cell Research</i> , 2012, 9, 77-86.	0.7	59
21	Bone Marrowâ€Derived Mesenchymal Stem Cells From Patients With Systemic Lupus Erythematosus Have a Senescenceâ€Associated Secretory Phenotype Mediated by a Mitochondrial Antiviral Signaling Proteinâ€Interferonâ€ $\beta$ Feedback Loop. <i>Arthritis and Rheumatology</i> , 2017, 69, 1623-1635.	5.6	56
22	Novel mHealth App to Deliver Geriatric Assessment-Driven Interventions for Older Adults With Cancer: Pilot Feasibility and Usability Study. <i>JMIR Cancer</i> , 2018, 4, e10296.	2.4	55
23	Effect of nitric oxide production and oxygen tension on progenitor preservation in ex vivo culture. <i>Experimental Hematology</i> , 1999, 27, 441-450.	0.4	53
24	P-Selectinâ€Coated Microtube for Enrichment of CD34+ Hematopoietic Stem and Progenitor Cells from Human Bone Marrow. <i>Clinical Chemistry</i> , 2008, 54, 77-85.	3.2	53
25	Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. <i>Blood Reviews</i> , 2018, 32, 235-248.	5.7	48
26	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	4.1	45
27	Flavonoid effects on normal and leukemic cells. <i>Leukemia Research</i> , 2003, 27, 517-527.	0.8	43
28	Use of eltrombopag, a thrombopoietin receptor agonist, in postâ€transplantation thrombocytopenia. <i>American Journal of Hematology</i> , 2012, 87, 743-745.	4.1	43
29	Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 228-241.	2.0	43
30	Cytopenia after CAR-T Cell Therapyâ€A Brief Review of a Complex Problem. <i>Cancers</i> , 2022, 14, 1501.	3.7	43
31	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
32	Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2022, 139, 1135-1146.	1.4	39
33	The Hematopoietic Stem Cell in Myelodysplasia. <i>Stem Cells</i> , 2004, 22, 590-599.	3.2	35
34	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
35	Acute myelogenous leukemiaâ€microenvironment interactions: Role of endothelial cells and proteasome inhibition. <i>Hematology</i> , 2005, 10, 483-494.	1.5	34
36	Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes. <i>Blood Reviews</i> , 2019, 36, 57-69.	5.7	34

#	ARTICLE	IF	CITATIONS
37	Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. <i>Blood Advances</i> , 2020, 4, 983-992.	5.2	34
38	Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 202-208.	2.0	33
39	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
40	Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404.	7.1	32
41	Response of Human CD34+Cells to CXCL1, CXCL2, and CXCL3 Chemokines: Implications for Cell Migration and Activation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2001, 10, 643-655.	1.8	31
42	Cytokine effects and role of adhesive proteins and Fc receptors in human macrophage-mediated antibody dependent cellular cytotoxicity. <i>Journal of Cellular Biochemistry</i> , 1991, 45, 381-390.	2.6	29
43	Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2335-2345.	2.0	28
44	A Phase 1 Trial of Eltrombopag in Patients Undergoing Stem Cell Transplantation after Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1745-1752.	2.0	27
45	Investigating the Feasibility of Stem Cell Enrichment Mediated by Immobilized Selectins. <i>Biotechnology Progress</i> , 2007, 23, 1463-1472.	2.6	26
46	Oral valacyclovir versus intravenous acyclovir in preventing herpes simplex virus infections in autologous stem cell transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 662-665.	2.0	25
47	Peri-Transplant Psychosocial Factors and Neutrophil Recovery following Hematopoietic Stem Cell Transplantation. <i>PLoS ONE</i> , 2014, 9, e99778.	2.5	25
48	Biomolecular Surfaces for the Capture and Reprogramming of Circulating Tumor Cells. <i>Journal of Bionic Engineering</i> , 2009, 6, 311-317.	5.0	24
49	A phase I study of decitabine and rapamycin in relapsed/refractory AML. <i>Leukemia Research</i> , 2013, 37, 1622-1627.	0.8	24
50	Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells. <i>MBio</i> , 2019, 10, .	4.1	24
51	Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia. <i>Cancers</i> , 2018, 10, 179.	3.7	22
52	Maintenance Tyrosine Kinase Inhibitors Following Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 472-479.	2.0	21
53	Eltrombopag treatment during induction chemotherapy for acute myeloid leukaemia: a randomised, double-blind, phase 2 study. <i>Lancet Haematology</i> , 2019, 6, e122-e131.	4.6	20
54	Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists. <i>Leukemia and Lymphoma</i> , 2021, 62, 387-398.	1.3	20

#	ARTICLE	IF	CITATIONS
55	Uproleselan (GMI-1271), an E-Selectin Antagonist, Improves the Efficacy and Safety of Chemotherapy in Relapsed/Refractory (R/R) and Newly Diagnosed Older Patients with Acute Myeloid Leukemia: Final, Correlative, and Subgroup Analyses. <i>Blood</i> , 2018, 132, 331-331.	1.4	19
56	Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. <i>Cancer Medicine</i> , 2016, 5, 3059-3067.	2.8	18
57	Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190.	5.2	18
58	Stem Cell Enrichment with Selectin Receptors: Mimicking the pH Environment of Trauma. <i>Sensors</i> , 2013, 13, 12516-12526.	3.8	15
59	Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 372-378.	0.8	15
60	Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in older adults: Current treatment and novel therapies. <i>Best Practice and Research in Clinical Haematology</i> , 2017, 30, 184-192.	1.7	15
61	Reducing the Need for HLA-Matched Platelet Transfusion. <i>New England Journal of Medicine</i> , 2021, 384, 2451-2452.	27.0	15
62	Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 520-527.	2.0	14
63	Comparison of outcomes of HCT in blast phase of <i>t(9;22) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
64	A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146.	2.0	14
65	Management of AML: Who do we really cure?. <i>Leukemia Research</i> , 2012, 36, 1475-1480.	0.8	13
66	Phenotypic, genotypic, and functional characterization of normal and acute myeloid leukemia-derived marrow endothelial cells. <i>Experimental Hematology</i> , 2016, 44, 378-389.	0.4	13
67	Improved outcomes in acute myeloid leukemia patients treated with washed transfusions. <i>American Journal of Hematology</i> , 2017, 92, E8-E9.	4.1	13
68	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1830-1838.	2.0	12
69	Circulating endocannabinoids during hematopoietic stem cell transplantation: A pilot study. <i>Neurobiology of Stress</i> , 2015, 2, 44-50.	4.0	12
70	Effects of Neddylation and mTOR Inhibition in Acute Myelogenous Leukemia. <i>Translational Oncology</i> , 2019, 12, 602-613.	3.7	12
71	Effect of Aging and Predonation Comorbidities on the Related Peripheral Blood Stem Cell Donor Experience: Report from the Related Donor Safety Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 699-711.	2.0	11
72	Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10.	1.2	11

#	ARTICLE	IF	CITATIONS
73	ABO identical and washed blood transfusions as candidate strategies to reduce early mortality in acute promyelocytic leukemia. <i>Leukemia Research</i> , 2017, 62, 1-3.	0.8	10
74	Developing and adapting a mobile health exercise intervention for older patients with myeloid neoplasms: A qualitative study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 909-914.	1.0	10
75	Persistence of HIV-1 Env-Specific Plasmablast Lineages in Plasma Cells after Vaccination in Humans. <i>Cell Reports Medicine</i> , 2020, 1, 100015.	6.5	10
76	SY-1425, a Potent and Selective RAR $\alpha$ Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 4-5.	1.4	10
77	Late Relapses After High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Diffuse Large B-cell Lymphoma in the Rituximab Era. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 145-151.	0.4	9
78	Economic and Practical Considerations in the Treatment of Oral Mucosal Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1748-1753.	2.0	9
79	Bone marrow mesenchymal stem cells from patients with SLE maintain an interferon signature during in vitro culture. <i>Cytokine</i> , 2020, 132, 154725.	3.2	9
80	GMI-1271 Improves Efficacy and Safety of Chemotherapy in R/R and Newly Diagnosed Older Patients with AML: Results of a Phase 1/2 Study. <i>Blood</i> , 2017, 130, 894-894.	1.4	9
81	Phenotypic, Genotypic, and Functional Characterization Of AML-Derived Endothelial Cells. <i>Blood</i> , 2013, 122, 1411-1411.	1.4	9
82	Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation. <i>Frontiers in Oncology</i> , 2012, 2, 86.	2.8	8
83	IFN $\gamma$ signaling inhibits osteogenesis in human SLE bone marrow. <i>Lupus</i> , 2020, 29, 1040-1049.	1.6	8
84	Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment. <i>JAAD Case Reports</i> , 2020, 6, 292-295.	0.8	8
85	Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. <i>Cancer Investigation</i> , 2011, 29, 439-50.	1.3	8
86	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7
87	Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820.	1.3	7
88	Trouble in the niche? Send in a statin. <i>Blood</i> , 2016, 128, 2877-2878.	1.4	6
89	Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells. <i>Leukemia and Lymphoma</i> , 2018, 59, 1717-1721.	1.3	6
90	Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117.	2.4	6

#	ARTICLE	IF	CITATIONS
91	A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 41-42.	1.4	6
92	MIP-1 $\alpha$ and TGF- $\beta$ Production in CD34+ Progenitor-Stromal Cell Coculture Systems: Effects of Progenitor Isolation Method and Cell-Cell Contact. <i>Blood Cells, Molecules, and Diseases</i> , 2000, 26, 261-275.	1.4	5
93	Surrogate end points for long-term outcomes in chronic myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2013, 54, 2103-2111.	1.3	5
94	Targeted therapy for treatment of patients with classical hairy cell leukemia. <i>Leukemia Research</i> , 2021, 102, 106522.	0.8	5
95	Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). <i>Blood</i> , 2018, 132, 2735-2735.	1.4	5
96	A Phase I/II Study of GMI-1271, a Novel E-Selectin Antagonist, in Combination with Induction Chemotherapy in Relapsed/Refractory and Elderly Previously Untreated Acute Myeloid Leukemia; Results to Date. <i>Blood</i> , 2016, 128, 4049-4049.	1.4	5
97	A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia. <i>Leukemia Research</i> , 2022, 112, 106749.	0.8	5
98	Can we incorporate geriatric assessment in the management of acute lymphoblastic leukemia in older adults?. <i>Journal of Geriatric Oncology</i> , 2018, 9, 296-301.	1.0	4
99	CNS Melioidosis in a Traveler Returning from Cabo, Mexico. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz005.	0.9	4
100	Marrow failure and aging: The role of $\alpha$ -Inflammaging. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101283.	1.7	4
101	Qualitative Study of Factors That Influence Treatment Decision-Making Among Community Oncologists and Older Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 2246-2246.	1.4	4
102	Phase 1 study of the angiopoietin 1/2 neutralizing peptibody, trebananib, in acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7082-7082.	1.6	4
103	When what you have is not enough: optimizing cord blood transplantation in adults. <i>Leukemia Research</i> , 2003, 27, 197-199.	0.8	3
104	Bcl-2 Inhibitor ABT-263 Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells. <i>Blood</i> , 2012, 120, 206-206.	1.4	3
105	Clinical and Biologic Effects Of The Angiopoietin 1/2 Neutralizing Peptibody, Trebananib (AMG 386), In Acute Myeloid Leukemia Patients. <i>Blood</i> , 2013, 122, 2701-2701.	1.4	3
106	Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RAR $\alpha$ Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 6-7.	1.4	3
107	Hypereosinophilic syndromes: an update. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 22, 5-10.	1.0	2
108	Modulation of Selectin-Mediated Adhesion of Flowing Lymphoma and Bone Marrow Cells by Immobilized SDF-1. <i>International Journal of Molecular Sciences</i> , 2014, 15, 15061-15072.	4.1	2

#	ARTICLE	IF	CITATIONS
109	Autologous stem cell rescue recipient with neutrophil tissue delivery detected prior to blood engraftment: A case report. <i>EJHaem</i> , 2020, 1, 330-333.	1.0	2
110	Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation,. <i>Blood</i> , 2011, 118, 3295-3295.	1.4	2
111	Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation. <i>Blood</i> , 2012, 120, 219-219.	1.4	2
112	Interleukin-1/Toll-like Receptor Inhibition Can Restore the Disrupted Bone Marrow Microenvironment in Mouse Model of Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 1510-1510.	1.4	2
113	Protocol for a pilot randomized controlled trial of a mobile health exercise intervention for older patients with myeloid neoplasms (GO-EXCAP 2). <i>Journal of Geriatric Oncology</i> , 2022, 13, 545-553.	1.0	2
114	Effect of hydrocortisone and interleukins 1 and 2 on eosinophil progenitors in hypereosinophilic states. <i>International Journal of Cell Cloning</i> , 1988, 6, 404-416.	1.6	1
115	Treatment patterns in low-grade non-Hodgkin's lymphomas: A single institution study. <i>Medical and Pediatric Oncology</i> , 1991, 19, 1-7.	1.0	1
116	Bone marrow failure syndromes. <i>Best Practice and Research in Clinical Haematology</i> , 2021, 34, 101288.	1.7	1
117	Access and Referral Barriers to Autologous and Allogeneic Hematopoietic Cell Transplantation in Adult Patients with Cancer: A Systematic Review with a Specific Focus on Geriatric Population. <i>Blood</i> , 2018, 132, 2245-2245.	1.4	1
118	Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival. <i>Blood</i> , 2014, 124, 3984-3984.	1.4	1
119	A Role for IL1RAP in Acute Myelogenous Leukemia Stem Cells Following Treatment and Progression. <i>Blood</i> , 2015, 126, 4266-4266.	1.4	1
120	Distinct Properties of Leukemia Stem Cells in Primary Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 685-685.	1.4	1
121	The CXCR4 Antagonist, AMD3100, Inhibits AML Transmigratory Activity but Does Not Alter Blast Proliferation or Survival.. <i>Blood</i> , 2004, 104, 2881-2881.	1.4	1
122	Evolution Of Acute Myelogenous Leukemia Stem Cell Properties Following Treatment and Progression. <i>Blood</i> , 2013, 122, 883-883.	1.4	1
123	A Specific Mesenchymal Stem and Progenitor Cell (MSPC) Subpopulation with a Multi-Potent Gene Signature Is Transcriptionally Altered in the Setting of Myelodysplastic Syndrome (MDS) in Primary Human Bone Marrow Aspirates. <i>Blood</i> , 2019, 134, 1708-1708.	1.4	1
124	Treatment Decision-Making and Decisional Support Experiences Among Acute Myeloid Leukemia Survivors. <i>Blood</i> , 2020, 136, 20-20.	1.4	1
125	Early Completion of Medical Orders for Life-Sustaining Treatment (MOLST) and Hospice Enrollment Are Associated with Improved End of Life (EOL) Quality Metrics in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2020, 136, 20-21.	1.4	1
126	The therapeutic potential of bedside art observation in hematologic cancer inpatients: a randomized controlled pilot study. <i>Supportive Care in Cancer</i> , 2022, 30, 3585.	2.2	1



#	ARTICLE	IF	CITATIONS
127	Hypereosinophilic syndromes: an update. International Journal of Clinical and Laboratory Research, 1996, 26, 5-10.	1.0	0
128	Hypereosinophilic syndromes: an update. International Journal of Clinical and Laboratory Research, 1996, 26, 5-7.	1.0	0
129	Acute promyelocytic leukemia—mobile and infiltrative. Leukemia Research, 2007, 31, 5-7.	0.8	0
130	CML: Defining the efficacy of targeted therapy with the TARGET system. Leukemia Research, 2011, 35, 575-576.	0.8	0
131	Emergence of JAK2-mutant primary myelofibrosis in myelodysplastic syndrome: rare case report, literature review, and implications for clonal progression. Journal of Hematopathology, 2012, 5, 135-139.	0.4	0
132	Mixed lineage acute leukemia: navigating the heterogeneity. European Journal of Haematology, 2015, 95, 375-376.	2.2	0
133	Plerixafor: potential role in acute leukemia therapy. Expert Opinion on Orphan Drugs, 2015, 3, 467-475.	0.8	0
134	Improved Methodology for Detection of Mutations in the BCR-ABL Fusion Gene That Cause Resistance to the Tyrosine Kinase Inhibitor Imatinib.. Blood, 2006, 108, 2341-2341.	1.4	0
135	Targeting Redox Homeostasis As a Means to Selectively Eradicate Primary Human Leukemia Cells,. Blood, 2011, 118, 3506-3506.	1.4	0
136	Phase I Study of Decitabine and Rapamycin in Relapsed/Refractory Acute Myelogenous Leukemia. Blood, 2012, 120, 3549-3549.	1.4	0
137	Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era. Blood, 2014, 124, 3999-3999.	1.4	0
138	Modulation of Interaction of Human Osteoprogenitor Cells with Hematopoietic Stem and Progenitor Cells. Blood, 2014, 124, 2933-2933.	1.4	0
139	Optimizing Effects of mTOR Inhibition in Acute Myelogenous Leukemia. Blood, 2015, 126, 4930-4930.	1.4	0
140	Bone Marrow Mesenchymal Stem Cells from Acute Myelogenous Leukemia Patients Demonstrate Adipogenic Differentiation Propensity. Blood, 2016, 128, 5064-5064.	1.4	0
141	ABO Identical and Washed Transfusions Are Candidate Strategies to Reduce Early Mortality in Acute Promyelocytic Leukemia (APL). Blood, 2016, 128, 4011-4011.	1.4	0
142	Role of RasGRP3 in EPO/EPOR Signaling and Transmigration of Human Hematopoietic CD34+ Cells. Blood, 2018, 132, 4531-4531.	1.4	0
143	Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Older Adults with Acute Myeloid Leukemia (AML). Blood, 2020, 136, 41-42.	1.4	0